| scholarly article | Q13442814 |
| P2093 | author name string | Q Li | |
| W Wang | |||
| A M Nilius | |||
| D M Hensey-Rudloff | |||
| P M Raney | |||
| R K Flamm | |||
| P2860 | cites work | In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi | Q46390314 |
| National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. | Q54137486 | ||
| Amphotericin B-resistant yeast infection in severely immunocompromised patients | Q68136440 | ||
| In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi | Q28343817 | ||
| In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species | Q28379025 | ||
| In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) | Q28379217 | ||
| In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species | Q28379527 | ||
| Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media | Q33682433 | ||
| Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase | Q33754208 | ||
| Lipopeptide inhibitors of fungal glucan synthase | Q34425782 | ||
| Detection of amphotericin B-resistant Candida isolates in a broth-based system | Q35113517 | ||
| In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. | Q35134781 | ||
| Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period | Q35821906 | ||
| Treatment of fungal infection in AIDS. | Q39076285 | ||
| Resistant candidiasis. | Q40563228 | ||
| Antifungal susceptibility testing | Q40795131 | ||
| Pulmonary aspergillosis: pathologic and pathogenetic features | Q40867007 | ||
| Fungal complications of transplantation: diagnosis, treatment and prevention | Q40970535 | ||
| National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species | Q45025194 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1242-6 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro activity of A-192411.29, a novel antifungal lipopeptide | |
| P478 | volume | 44 |
| Q53659256 | Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I). |
| Q44301666 | In vivo characterization of A-192411: a novel fungicidal lipopeptide (II). |
| Q46576615 | New agents for the treatment of systemic fungal infections--current status. |
| Q40409386 | Pharmacological agents in development for invasive aspergillosis |
Search more.